• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    New Drug Application (NDA): 217369
    Company: BIOGEN INC
    • Email
    • Medication Guide

    Products on NDA 217369

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    ZURZUVAE ZURANOLONE 20MG CAPSULE;ORAL Prescription None Yes No
    ZURZUVAE ZURANOLONE 25MG CAPSULE;ORAL Prescription None Yes No
    ZURZUVAE ZURANOLONE 30MG CAPSULE;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217369

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes
    08/04/2023 ORIG-2 Approval Type 1 - New Molecular Entity PRIORITY Federal Register Notice
    Label (PDF)
    Letter (PDF)
    Review
    FR Notice of DEA Scheduling; Date of Approval – October 31, 2023
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note
    04/20/2026 SUPPL-3 Labeling-Package Insert, Labeling-Container/Carton Labels, Labeling-Medication Guide Letter (PDF)

    Label is not available on this site.

    07/31/2024 SUPPL-1 Labeling-Package Insert, Labeling-Container/Carton Labels, Labeling-Medication Guide Label (PDF)
    Letter (PDF)

    Labels for NDA 217369

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note
    07/31/2024 SUPPL-1 Labeling-Package Insert Label (PDF)
    07/31/2024 SUPPL-1 Labeling-Container/Carton Labels Label (PDF)
    07/31/2024 SUPPL-1 Labeling-Medication Guide Label (PDF)
    08/04/2023 ORIG-2 Approval Label (PDF)
    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    5/15/2026Outperform
    Evercore ISI
    4/22/2026$225.00Neutral → Buy
    UBS
    4/20/2026$250.00Equal Weight → Overweight
    Wells Fargo
    4/14/2026$214.00Neutral → Overweight
    Piper Sandler
    2/20/2026$185.00Equal Weight
    Barclays
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    1/7/2026$185.00Neutral
    UBS
    12/10/2025$143.00Hold → Reduce
    HSBC Securities
    More analyst ratings

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    Submission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

    Data presentations across multiple kidney diseases illustrate the breadth of Biogen's nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC). "Our presence across two key medical congresses highlights the momentum of our newly broadened nephrology portfolio, which

    6/3/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    SEC Filings

    View All

    Biogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    5/14/26 8:31:16 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.

    SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)

    5/6/26 11:00:55 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Biogen Inc.

    10-Q - BIOGEN INC. (0000875045) (Filer)

    4/29/26 6:40:54 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of Corporate Development Keeney Adam converted options into 939 shares and covered exercise/tax liability with 455 shares, increasing direct ownership by 8% to 6,365 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/26 4:11:57 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Godbout Sean

    4 - BIOGEN INC. (0000875045) (Issuer)

    4/3/26 4:05:27 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President and CEO Viehbacher Christopher

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:18:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/20/24 9:13:26 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Biogen

    Evercore ISI resumed coverage of Biogen with a rating of Outperform

    5/15/26 8:16:23 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by UBS with a new price target

    UBS upgraded Biogen from Neutral to Buy and set a new price target of $225.00

    4/22/26 7:42:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Biogen from Equal Weight to Overweight and set a new price target of $250.00

    4/20/26 8:20:15 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Financials

    Live finance-specific insights

    View All

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

    Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M

    6/1/26 1:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Completes Acquisition of Apellis Pharmaceuticals

    CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen's near-term growth outlook and accelerating the Company's expansion into nephrology. Together, the products recorded $689 million in net product revenue in 2025. This transaction will strengthen Biogen's revenue and EPS growth potential by being accretive to Bioge

    5/14/26 8:35:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

    NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE:BFAM) will replace Tri Pointe Homes Inc. (NYSE:TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take

    5/7/26 6:01:00 PM ET
    $APLS
    $BFAM
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Consumer Discretionary

    Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

    Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ:BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR) and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her know

    5/5/26 6:37:00 AM ET
    $BIIB
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations